Precise mapping of increased sialylation pattern and the expression of acute phase proteins accompanying murine tumor progression in BALB/c mouse by integrated sera proteomics and glycomics

Journal of Proteome Research

Volumn 7, Issue 8, 2008, Pages 3293-3303

  Lin, Shu Yu ^a   Chen, Yi Yun ^a   Fan, Yao Yun ^b   Lin, Chia Wei ^b   Chen, Shui Tsung ^b   Wang, Andrew H J ^a,b   Khoo, Kay Hooi ^a,b  

^a ACADEMIA SINICA   (Taiwan)

^b INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

Author keywords

Acute phase proteins; Ascitic fluids; Glycomics; Mass spectrometry; Serum proteomics

Indexed keywords

AMYLOID P COMPONENT; BIOLOGICAL MARKER; HAPTOGLOBIN; ACUTE PHASE PROTEIN; GLYCOPEPTIDE; GLYCOPROTEIN; SIALIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; BREAST TUMOR; COLON TUMOR; CONTROLLED STUDY; GLYCOBIOLOGY; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SIALYLATION; TUMOR GROWTH; ANIMAL; CANCER TRANSPLANTATION; EXPERIMENTAL NEOPLASM; FEMALE; GLYCOSYLATION; LIQUID CHROMATOGRAPHY; MALE; METABOLISM; PATHOLOGY; TANDEM MASS SPECTROMETRY;

MURINAE; MUS;

ACUTE-PHASE PROTEINS; ANIMALS; CHROMATOGRAPHY, LIQUID; COLONIC NEOPLASMS; FEMALE; GLYCOMICS; GLYCOPEPTIDES; GLYCOPROTEINS; GLYCOSYLATION; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PROTEOMICS; SIALIC ACIDS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 53049094383     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr800093b     Document Type: Article

References (51)

1. Ciordia, S.; de Los Rios, V.; Albar, J. P. Contributions of advanced proteomics technologies to cancer diagnosis. Clin. Transl. Oncol. 2006, 8 (8), 566-80.
2. Maurya, P.; Meleady, P.; Dowling, P.; Clynes, M. Proteomic approaches for serum biomarker discovery in cancer. Anticancer Res. 2007, 27 (3A), 1247-55.
3. van der Merwe, D. E.; Oikonomopoulou, K.; Marshall, J.; Diamandis, E. P. Mass spectrometry: uncovering the cancer proteome for diagnostics. Adv. Cancer Res. 2007, 96, 23-50.
4. Comunale, M. A.; Lowman, M.; Long, R. E.; Krakover, J.; Philip, R.; Seeholzer, S.; Evans, A. A.; Hann, H. W.; Block, T. M.; Mehta, A. S. Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res. 2006, 5 (2), 308-15.
5. Durham, M.; Regnier, F. E. Targeted glycoproteomics: serial lectin affinity chromatography in the selection of O-glycosylation sites on proteins from the human blood proteome. J Chromatogr. A 2006, 1132(1-2), 165-73.
6. Zhao, J.; Simeone, D. M.; Heidt, D.; Anderson, M. A.; Lubman, D. M. Comparative serum glycoproteomics using lectin selected sialic acid glycoproteins with mass spectrometric analysis: application to pancreatic cancer serum. J Proteome Res. 2006, 5 (7), 1792-802.
7. Kannagi, R. Molecular mechanism for cancer-associated induction of sialyl Lewis X and sialyl Lewis A expression-The Warburg effect revisited. Glycoconj. J. 2004, 20 (5), 353-64.
8. Kannagi, R.; Izawa, M.; Koike, T.; Miyazaki, K.; Kimura, N. Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Set 2004, 95 (5), 377-84.
9. Kannagi, R.; Fukushi, Y.; Tachikawa, T.; Noda, A.; Shin, S.; Shigeta, K.; Hiraiwa, N.; Fukuda, Y.; Inamoto, T.; Hakomori, S.; et al. Quantitative and qualitative characterization of human cancer-associated serum glycoprotein antigens expressing fucosyl or sialylfucosyl type 2 chain polylactosamine. Cancer Res. 1986, 46 (5), 2619-26.
10. Satoh, H.; Ishikawa, H.; Kamma, H.; Yamashita, Y. T.; Takahashi, H.; Ohtsuka, M.; Hasegawa, S. Serum sialyl lewis X-i antigen levels in non-small cell lung cancer: correlation with distant metastasis and survival. Clin. Cancer Res. 1997, 3 (4), 495-9.
11. Aoyagi, Y.; Suzuki, Y.; lgarashi, K.; Saitoh, A.; Oguro, M.; Yokota, T.; Mori, S.; Nomoto, M.; Isemura, M.; Asakura, H. The usefulness of simultaneous determinations of glucosaminylation and fucosylation indices of alpha-fetoprotein in the differential diagnosis of neoplastic diseases of the liver. Cancer 1991, 67 (9), 2390-4.
12. Naitoh, A.; Aoyagi, Y.; Asakura, H. Highly enhanced fucosylation of serum glycoproteins in patients with hepatocellular carcinoma. J Gastroenterol. Hepatol. 1999, 14 (5), 436-45.
13. Barrabes, S.; Pages-Pons, L.; Radcliffe, C. M.; Tabares, G.; Fort, E.; Royle, L.; Harvey, D. J.; Moenner, M.; Dwek, R. A.; Rudd, P. M.; De Llorens, R.; Peracaula, R. Glycosylation of serum ribonuclease 1 indicates a major endothelial origin and reveals an increase in core fucosylation in pancreatic cancer. Glycobiology 2007, 17 (4), 388-400.
14. Itoh, N.; Sakaue, S.; Nakagawa, H.; Kurogochi, M.; Ohira, H.; Deguchi, K.; Nishimura, S. I.; Nishimura, M. Analysis of N-glycan in serum glycoproteins from db/db mice and humans with type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 2007, 293 (4), E1069-77.
15. Kam, R. K.; Poon, T. C.; Chan, H. L.; Wong, N.; Hui, A. Y.; Sung, I. J. High-Throughput Quantitative Profiling of Serum N-Glycome by MALDI-TOF Mass Spectrometry and N-Glycomic Fingerprint of Liver Fibrosis. Clin. Chem. 2007, 53 (7), 1254-63.
16. Kirmiz, C.; Li, B.; An, H. J.; Clowers, B. H.; Chew, H. K.; Lam, K. S.; Ferrige, A.; Alecio, R.; Borowsky, A. D.; Sulaimon, S.; Lebrilla, C. B.; Miyamoto, S. A serum glycomics approach to breast cancer biomarkers. Mol. Cell. Proteomics 2007, 6 (1), 43-55.
17. Kyselova, Z.; Mechref, Y.; Al Bataineh, M. M.; Dobrolecki, L. E.; Hickey, R. J.; Vinson, J.; Sweeney, C. J.; Novotny, M. V. Alterations in the serum glycome due to metastatic prostate cancer. J Proteome Res. 2007, 6 (5), 1822-32.
18. Chen, J. H.; Chang, Y. W.; Yao, C. W.; Chiueh, T. S.; Huang, S. C; Chien, K. Y.; Chen, A.; Chang, F. Y.; Wong, C. H.; Chen, Y. J. Plasma proteome of severe acute respiratory syndrome analyzed by two-dimensional gel electrophoresis and mass spectrometry. Proc. Natl. Acad. Set U.S.A. 2004, 101 (49), 17039-44.
19. Duan, X; Yarmush, D. M.; Berthiaume, F.; Jayaraman, A.; Yarmush, M. L. A mouse serum two-dimensional gel map: application to profiling burn injury and infection. Electrophoresis 2004, 25 (17), 3055-65.
20. Juan, H. F.; Chen, J. H.; Hsu, W. T.; Huang, S. C.; Chen, S. T.; Yi- Chung Lin, J.; Chang, Y. W.; Chiang; C. Y.; Wen, L. L.; Chan, D. C; Liu, Y. C; Chen, Y. J. Identification of tumor-associated plasma biomarkers using proteomic techniques: from mouse to human. Proteomics 2004, 4 (9), 2766-75.
21. Le, L.; Chi, K.; Tyldesley, S.; Flibotte, S.; Diamond, D. L.; Kuzyk, M. A.; Sadar, M. D. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin. Chem. 2005, 51 (4), 695-707.
22. Chiriva-Internati, M.; Grizzi, F.; Weidanz, J. A.; Ferrari, R.; Yuefei, Y., Velez, B.; Shearer, M. H.; Lowe, D. B.; Frezza, E. E.; Cobos, E.; Kast, W. M.; Kennedy, R. C. A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Spl7. J Immunol. Methods 2007, 321 (1-2), 86-93.
23. Sato, N.; Gleave, M. E.; Bruchovsky, N.; Rennie, P. S.; Beraldi, E.; Sullivan, L. D. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. Cancer Res. 1997, 57(8), 1584-9.
24. Stephenson, R. A.; Dinney, C. P.; Gohji, K.; Ordonez, N. G.; Killion, J. J.; Fidler, I. J. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl. Cancer Inst. 1992, 84 (12), 951-7.
25. Chen, Y. Y.; Lin, S. Y.; Yeh, Y. Y.; Hsiao, H. H.; Wu, C. Y.; Chen, S. T.; Wang, A. H. A modified protein precipitation procedure for efficient removal of albumin from serum. Electrophoresis 2005, 26 (11), 2117-27.
26. Lee, C. L.; Hsiao, H. H.; Lin, C. W.; Wu, S. P.; Huang, S. Y.; Wu, C. Y.; Wang, A. H.; Khoo, K. H. Strategic shotgun proteomics approach for efficient construction of an expression map of targeted protein families in hepatoma cell lines. Proteomics 2003, 3 (12), 2472-86.
27. Ritchie, M. A.; Gill, A. C.; Deery, M. J.; Lilley, K. Precursor ion scanning for detection and structural characterization of heterogeneous glycopeptide mixtures. J Am. Soc. Mass Spectrom. 2002, 13 (9), 1065-77.
28. Dell, A.; Reason, A. J.; Khoo, K. H.; Panico, M.; McDowell, R. A.; Morris, H. R. Mass spectrometry of carbohydrate-containing biopolymers. Methods Enzymol. 1994, 230, 108-32.
29. Yu, S. Y.; Wu, S. W.; Khoo, K. H. Distinctive characteristics of MALDI-Q/TOF and TOF/TOF tandem mass spectrometry for sequencing of permethylated complex type N-glycans. Glycoconj. J. 2006, 23 (5-6), 355-69.
30. Bjorhall, K.; Miliotis, T.; Davidsson, P. Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples. Proteomics 2005, 5 (1), 307-17.
31. Chromy, B. A.; Gonzales, A. D.; Perkins, J.; Choi, M. W.; Corzett, M. H.; Chang, B. C; Corzett, C. H.; McCutchen-Maloney, S. L. Proteomic analysis of human serum by two-dimensional differential gel electrophoresis after depletion of high-abundant proteins. J Proteome Res. 2004, 3 (6), 1120-7.
32. Fu, Q.; Bovenkamp, D. E.; Van Eyk, J. E. A rapid, economical, and reproducible method for human serum delipidation and albumin and IgG removal for proteomic analysis. Methods Mol. Biol. 2007, 357, 365-71.
33. Morley, J. J.; Kushner, I. Serum C-reactive protein levels in disease. Ann. N.Y. Acad. Sci. 1982, 389, 406-18.
34. Chavan, M. M.; Kawle, P. D.; Mehta, N. G. Increased sialylation and defucosylation of plasma proteins are early events in the acute phase response. Glycobiology 2005, 15 (9), 838-48.
35. Heegaard, P. M. Changes in serum glycoprotein glycosylation during experimental inflammation in mice are general, unrelated to protein type, and opposite changes in man and rat: studies on mouse serum alpha 1-acid glycoprotein, alpha 1-esterase, and alpha 1-protease inhibitor. Inflammation 1992, 16 (6), 631-44.
36. Turner, G. A.; Skillen, A. W.; Buamah, P.; Guthrie, D.; Welsh, J.; Harrison, J.; Kowalski, A. Relation between raised concentrations of fucose, sialic acid, and acute phase proteins in serum from patients with cancer: choosing suitable serum glycoprotein markers. J Clin. Pathol. 1985, 38 (5), 588-92.
37. Kawano, T.; Koyama, S.; Takematsu, H.; Kozutsumi, Y.; Kawasaki, H.; Kawashima, S.; Kawasaki, T.; Suzuki, A. Molecular cloning of cytidine monophospho-N-acetylneuraminic acid hydroxylase. Regulation of species- and tissue-specific expression of N-glycolylneuraminic acid. J Biol. Chem. 1995, 270 (27), 16458-63.
38. Coddeville, B.; Regoeczi, E.; Strecker, G.; Plancke, Y.; Spik, G. Structural analysis of trisialylated biantennary glycans isolated from mouse serum transferrin. Characterization of the sequence Neu5Gc(alpha 2-3)Gal(beta l-3)[Neu5Gc(alpha 2-6)]GlcNAc-(beta l-2)Man. Biochim. Biophys. Acta 2000, 1475 (3), 321-8.
39. Ang, I. L.; Poon, T. C.; Lai, P. B.; Chan, A. T.; Ngai, S. M.; Hui, A. Y.; Johnson, P. J.; Sung, J. J. Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach. J Proteome Res. 2006, 5 (10), 2691-700.
40. Okuyama, N.; Ide, Y.; Nakano, M.; Nakagawa, T.; Yamanaka, K.; Moriwaki, K.; Murata, K.; Ohigashi, H.; Yokoyama, S.; Eguchi, H.; Ishikawa, O.; Ito, T.; Kato, M.; Kasahara, A.; Kawano, S.; Gu, J.; Taniguchi, N.; Miyoshi, E. Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int. J. Cancer 2006, 118 (11), 2803-8.
41. Turner, G. A. Haptoglobin. A potential reporter molecule for glycosylation changes in disease. Adv. Exp. Med. Biol. 1995, 376, 231-8.
42. Huddleston, M. J.; Bean, M. F.; Carr, S. A. Collisional fragmentation of glycopeptides by electrospray ionization LC/MS and LC/MS/MS: methods for selective detection of glycopeptides in protein digests. Anal. Chem. 1993, 65 (7), 877-84.
43. Yasukawa, Z.; Sato, C; Kitajima, K. Inflammation-dependent changes in alpha2,3-, alpha2,6-, and alpha2,8-sialic acid glycotopes on serum glycoproteins in mice. Glycobiology 2005, 15 (9), 827-37.
44. Irie, A.; Koyama, S.; Kozutsumi, Y.; Kawasaki, T.; Suzuki, A. The molecular basis for the absence of N-glycolylneuraminic acid in humans. J Biol. Chem. 1998, 273 (25), 15866-71.
45. Varki, A. N-glycolylneuraminic acid deficiency in humans. Biochimie 2001, 83 (7), 615-22.
46. Brinkman-Van der Linden, E. C; Sjoberg, E. R.; Juneja, L. R.; Crocker, P. R.; Varki, N.; Varki, A. Loss of N-glycolylneuraminic acid in human evolution. Implications for sialic acid recognition by siglecs. J Biol. Chem. 2000, 275 (12), 8633-40.
47. Lattova, E.; Varma, S.; Bezabeh, T.; Petrus, L.; Perreault, H. Mass spectrometric profiling of N-linked oligosaccharides and uncommon glycoform in mouse serum with head and neck tumor. J Am. Soc. Mass Spectrom. 2008, in press.
48. Tsuchida, A.; Okajima, T.; Furukawa, K.; Ando, T.; Ishida, H.; Yoshida, A.; Nakamura, Y.; Kannagi, R.; Kiso, M.; Furukawa, K. Synthesis of disialyl Lewis a (Le(a)) structure in colon cancer cell lines by a sialyltransferase, ST6GalNAc VI, responsible for the synthesis of alpha-series gangliosides. J. Biol. Chem. 2003, 278 (25), 22787-94.
49. Diamandis, E. P. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics. Clin. Chem. 2003, 49 (8), 1272-5.
50. Steinert, R.; von Hoegen, P.; Fels, L. M.; Gunther, K.; Lippert, H.; Reymond, M. A. Proteomic prediction of disease outcome in cancer: clinical framework and current status. Am. J. Pharmaco-genomics 2003, 3 (2), 107-15.
51. Bhat, V. B.; Choi, M. H.; Wishnok, J. S.; Tannenbaum, S. R. Comparative plasma proteome analysis of lymphoma-bearing SJL mice. J Proteome Res. 2005, 4 (5), 1814-25.